摘要
目的观察恩度(重组人血管内皮抑素注射液)联合顺铂治疗恶性血性胸腔积液的有效性和安全性。方法将90例恶性血性胸腔积液的晚期肿瘤患者分为治疗组(恩度+顺铂)和对照组(顺铂),对照组胸腔内灌注顺铂(DDP)40 mg/m2,1次/w,连续2 w;治疗组顺铂给药同前,同时加恩度30 mg胸腔内给药,2次/w,连续2 w。比较两组疗效和不良反应。结果所有患者均可进行客观疗效及安全性评价,治疗组CR 10例,PR 19例,NC+PD 16例,有效率为64.4%(29/45);对照组CR 4例,PR 14例,NC+PD 27例,有效率为40.0%(18/45),两组间有效率具有显著差异(P<0.05);治疗组患者生活质量改善率(51.1%)较对照组(24.4%)显著提高(P<0.05);两组药物毒副反应均不明显。胸腔灌注后,治疗组较对照组胸水中红细胞数显著减少(P<0.05)。结论恩度联合DDP能较好治疗恶性血性胸腔积液,减轻临床症状,改善患者生活质量,安全性好,值得临床进一步研究。
Objective To observe the efficacy and safety of recombinant human endostatin injection （endostar）, a new molecular targeted anti -tumor agent, combined with DDP chemotherapy on malignant bloody pleural effusion. Methods 90 patients were randomly divided into treatment group （ endostar combined with DDP, n = 45 ） and control group （ DDP, n = 45 ）. DDP at 40 mg/m^2 was injected into pleural cavity in control group once a week for 2 w. The same dose and frequency of DDP combined with 30 mg of endostar twice a week for 2 w was given in treatment group. The efficacy and safety were compared between the two groups 4 w after treatment. Results There were 10 cases of complete remission（ CR）, 19 cases of partial remission（PR） and 16 cases of no change plus progressive disease （ NC ＋ PD） in treatment group with responsive rate （RR） of 64.4% （ 29/45 ）. 4 cases of CR, 14 cases of PR and 27 cases of NC ＋ PD were found in control group with RR of 40.0% （ 18/45 ）. There was a significant difference in effective rate between the two groups（ P 〈 0.05 ）. The improvement rate of quality of life（QOL） in treatment group was significantly higher than that in control group（51. 1% versus 24.4% ,P 〈 0.05 ）. Drug adverse reactions in both groups were not obvious. Red blood cells in pleural fluid was significantly fewer in treatment group than that in control group after thoracic infusion （ P 〈0. 05）. Conclusion Endostar combined with DDP thoracic infusion can better treat malignant bloody pleural effusion, reduce clinical symptoms and improve the patients＇ QOL. It is a safe regimen worthy of further clinical study.
出处
《西南国防医药》
CAS
2011年第7期723-725,共3页
Medical Journal of National Defending Forces in Southwest China
关键词
血性胸腔积液
恶性
重组人血管内皮抑素
顺铂
胸腔灌注
malignant bloody pleural effusion
recombinant human endostatin
DDP
thoracic infusion
